Emergent Biosolutions Inc (NYSE:EBS) Chairman Fuad El-Hibri sold 15,000 shares of Emergent Biosolutions stock in a transaction that occurred on Monday, July 9th. The shares were sold at an average price of $53.61, for a total transaction of $804,150.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Emergent Biosolutions traded up $0.16, reaching $53.88, on Wednesday, MarketBeat reports. 289,425 shares of the company were exchanged, compared to its average volume of 347,790. Emergent Biosolutions Inc has a 12 month low of $32.48 and a 12 month high of $55.94. The firm has a market capitalization of $2.67 billion, a P/E ratio of 28.45, a price-to-earnings-growth ratio of 1.14 and a beta of 1.32. The company has a current ratio of 5.49, a quick ratio of 3.70 and a debt-to-equity ratio of 0.02.
Emergent Biosolutions (NYSE:EBS) last announced its earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.22 by ($0.25). Emergent Biosolutions had a return on equity of 10.39% and a net margin of 11.96%. The company had revenue of $117.80 million for the quarter, compared to the consensus estimate of $140.42 million. During the same period last year, the firm posted $0.23 EPS. The company’s revenue was up .8% compared to the same quarter last year. equities research analysts anticipate that Emergent Biosolutions Inc will post 2.35 EPS for the current fiscal year.
Emergent Biosolutions declared that its Board of Directors has initiated a share buyback program on Thursday, March 22nd that authorizes the company to buyback $50.00 million in outstanding shares. This buyback authorization authorizes the biopharmaceutical company to buy shares of its stock through open market purchases. Shares buyback programs are typically a sign that the company’s management believes its stock is undervalued.
EBS has been the topic of a number of recent analyst reports. Wells Fargo & Co reissued a “market perform” rating on shares of Emergent Biosolutions in a research report on Wednesday, April 25th. Zacks Investment Research raised shares of Emergent Biosolutions from a “hold” rating to a “buy” rating and set a $59.00 price target on the stock in a research report on Monday, April 30th. Cantor Fitzgerald initiated coverage on shares of Emergent Biosolutions in a research report on Monday, June 11th. They issued a “buy” rating and a $62.00 price target on the stock. Finally, Argus began coverage on shares of Emergent Biosolutions in a research report on Wednesday, June 13th. They issued a “buy” rating and a $62.00 price target on the stock. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $58.29.
A number of hedge funds have recently made changes to their positions in the stock. Xact Kapitalforvaltning AB increased its position in Emergent Biosolutions by 43.0% during the second quarter. Xact Kapitalforvaltning AB now owns 9,309 shares of the biopharmaceutical company’s stock worth $470,000 after acquiring an additional 2,800 shares during the period. Mount Yale Investment Advisors LLC bought a new position in Emergent Biosolutions during the first quarter worth $234,000. Allianz Asset Management GmbH increased its position in Emergent Biosolutions by 60.9% during the first quarter. Allianz Asset Management GmbH now owns 112,858 shares of the biopharmaceutical company’s stock worth $5,942,000 after acquiring an additional 42,728 shares during the period. Summit Trail Advisors LLC increased its position in Emergent Biosolutions by 11.1% during the first quarter. Summit Trail Advisors LLC now owns 36,521 shares of the biopharmaceutical company’s stock worth $1,379,000 after acquiring an additional 3,637 shares during the period. Finally, Principal Financial Group Inc. increased its position in Emergent Biosolutions by 2.6% during the first quarter. Principal Financial Group Inc. now owns 292,075 shares of the biopharmaceutical company’s stock worth $15,377,000 after acquiring an additional 7,367 shares during the period. 83.08% of the stock is currently owned by institutional investors and hedge funds.
About Emergent Biosolutions
Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.